← Back to patent-cliff list
Budesonide Sustained-release Capsules(Everest Medicine)
Tier C — Watch / tradeBudesonide Sustained-release Capsules(Everest Medicine)
Singapore
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：GR
Indications (approved)：免疫球蛋白a肾病
Regional status
US
-
EU
-
China
Phase III
2022-12-09
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Budesonide Sustained-release Capsules(Everest Medicine)?
Approved indications include: 免疫球蛋白a肾病.
When does the Budesonide Sustained-release Capsules(Everest Medicine) patent expire?
No public expiry year is available for Budesonide Sustained-release Capsules(Everest Medicine) yet; this page updates once verified.
How do I get a quote for Budesonide Sustained-release Capsules(Everest Medicine) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03